We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Mechanical Tissue Resuscitation Technology Shows Promise Preventing Cell Death Following Brain Injury

By LabMedica International staff writers
Posted on 24 Apr 2012
Scientists looking for an effective treatment for traumatic brain injury have found that the size and extent of damaged tissue can be reduced by using a new device to prevent cell death.

The research, the focus of a three-year, USD 1.5 million study funded by the US Department of Defense (Arlington, VA, USA), was published April 2012 in the journal Neurosurgery. More...
The technology evaluated in lab rats, is called mechanical tissue resuscitation (MTR) and uses negative pressure to create an environment that fosters cell survival.

Louis C. Argenta, MD, and Michael Morykwas, PhD, professors from Wake Forest Baptist Medical Center (Winston-Salem, NC, USA) department of plastic surgery and reconstructive surgery, and a multidisciplinary group of colleagues at Wake Forest Baptist, have more than 15 years of experience working with negative pressure devices to successfully treat wounds and burns. In this study, the team used MTR to remove fluid and other toxins that cause cell death from an injury site deep in the brain.

When the brain is injured by blunt force, explosion, or other trauma, the cells at the impact site are irreversibly damaged and they die. In the region surrounding the wound, injured cells release toxic compounds that cause the brain to swell and restrict blood flow and oxygen levels. This process results in more extensive cell death, which affects brain function. Dr. Argenta and his colleagues targeted these injured brain cells to determine if removing the fluid and toxic substances that lead to cell death could help improve survival of the damaged cells.

In the study, a bioengineered material matrix was positioned directly on the injured area in the brain and attached to a flexible tube connected to a microcomputer vacuum pump. The pump delivered a carefully controlled vacuum to the injured brain for 72 hours drawing fluid from the injury site.

The brain injuries treated with the device showed a considerable drop in brain swelling and release of toxic substances when compared to untreated injuries. Brains treated with the device revealed that over 50% more brain tissue could be preserved compared to nontreated animals. Behavioral function tests demonstrated that function was returned more rapidly in the MTR treated group.

“We have been very gratified by the results thus far. This study demonstrates that by working together a multidisciplinary group of researchers can develop new technology that could be used one day at the hospital bedside,” said Dr. Argenta.

The researchers are now assessing the same technology in stroke and brain hemorrhage models. “The Department of Defense has identified this as an area that is ripe for medical advancement,” said study coauthor Stephen B. Tatter, MD, PhD, professor of neurosurgery at Wake Forest Baptist Medical Center. “We believe it will soon be ready for a clinical trial.”

Related Links:

Wake Forest Baptist Medical Center



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.